(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy
Launched by HOFFMANN-LA ROCHE · Jul 19, 2006
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients \>=18 years of age;
- • type 1 or type 2 diabetes;
- • stable glycemic control for \>=3 months;
- • diabetic nephropathy.
- Exclusion Criteria:
- • women who are pregnant, breastfeeding, or unwilling to use a reliable contraceptive method;
- • previous treatment with erythropoietin or other erythropoietic substance;
- • nondiabetic renal disease, nephrotic syndrome;
- • blood transfusion within the 3 months prior to enrollment;
- • administration of any investigational drug within 30 days preceding the study start, and during the study.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Madrid, , Spain
Valencia, , Spain
Mexico City, , Mexico
Cambridge, , United Kingdom
Miskolc, , Hungary
Belfast, , United Kingdom
Barcelona, , Spain
Monterrey, , Mexico
Bialystok, , Poland
Singapore, , Singapore
Heidelberg, , Germany
Sao Paulo, , Brazil
Ancona, , Italy
Liberec, , Czech Republic
Alexandroupolis, , Greece
Nikea, , Greece
Chiang Mai, , Thailand
Lecco, , Italy
La Coruna, , Spain
Budapest, , Hungary
Pecs, , Hungary
Roskilde, , Denmark
Valencia, , Spain
London, , United Kingdom
Salford, , United Kingdom
Ioannina, , Greece
Linz, , Austria
Thessaloniki, , Greece
Middlesborough, , United Kingdom
Chihuahua, , Mexico
Athens, , Greece
Katowice, , Poland
Milano, , Italy
Milano, , Italy
Szombathely, , Hungary
Bialystok, , Poland
Baracaldo, , Spain
Veria, , Greece
Cinisello Balsamo, , Italy
Athens, , Greece
Moscow, , Russian Federation
Stockholm, , Sweden
Jihlava, , Czech Republic
Koebenhavn, , Denmark
Jyvaeskylae, , Finland
Muenchen, , Germany
Cagliari, , Italy
Caserta, , Italy
Desio, , Italy
Messina, , Italy
Katowice, , Poland
Radom, , Poland
Moscow, , Russian Federation
Galdakao, , Spain
Stockholm, , Sweden
Bangkok, , Thailand
Chonburi, , Thailand
Sheffield, , United Kingdom
Wrexham, , United Kingdom
Patients applied
Trial Officials
Ebenhard Ritz, Prof. Dr.
Principal Investigator
unaffliated
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials